跳至主要内容
临床试验/NCT00659100
NCT00659100已完成3 期

A 3-Month, Open-Label, Pharmacy-Based, Actual-Use Trial in a Simulated Over-The-Counter (OTC) Environment to Assess Self-Selection and Consumer Use Patterns of Gabapentin 250 mg for Occasional Sleeplessness

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 个研究点 分布在 1 个国家目标入组 1,254 人开始时间: 2006年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
1,254
试验地点
1
主要终点
Subject compliance with directions for use (number of capsules per dose and the number of doses per day)

研究概览

简要总结

The purpose of this study is to assess consumers' behaviors related to gabapentin self- selection and use, relative to warnings and directions for use, as described in the proposed over-the-counter (OTC) product label.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age of 18 years or older with symptoms of sleeplessness
  • Provided informed consent

排除标准

  • Contraindications to use of gabapentin

研究组 & 干预措施

A

Experimental

干预措施: Gabapentin (Drug)

结局指标

主要结局

Subject compliance with directions for use (number of capsules per dose and the number of doses per day)

时间窗: Throughout Day 90

Proportion of subjects who selected or purchased gabapentin for use (patients had symptoms consistent with indication and no contraindications)

时间窗: Throughout Day 90

次要结局

  • Adverse events(Duration of study)

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验